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ABSTRACT 
Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) are auto-immune 
conditions resulting from infection with group A streptococcus. Current management of these 
conditions includes secondary antibiotic prevention. This comprises regular 3 to 4 weekly 
long-acting intramuscular benzathine penicillin injections.  
Secondary antibiotic prevention aims to protect individuals against reinfection with 
group A streptococcus thereby preventing recurrent ARF and the risk of further damage to 
the heart valves However, uptake of benzathine penicillin can be poor leaving patients at risk 
of avoidable and progressive heart damage.  
This review utilizes the Chronic Care Model as a framework to discuss initiatives to 
enhance the delivery of secondary antibiotic prophylaxis for ARF and RHD. Results from the 
search strategy utilized revealed that there is limited pertinent published evidence. The 
evidence that is available suggests that register/recall systems, dedicated health teams for 
delivery of secondary antibiotic prophylaxis, education about ARF and RHD, linkages with 
the community (particularly between health services and schools) and strong staff-patient 
relationships may be important. However, it is difficult to generalize findings from individual 
studies to other settings and high quality studies are lacking.  
While secondary antibiotic prophylaxis is an effective treatment for those with ARF 
or RHD, the difficulties in implementing effective programs that reduce the burden of ARF 
and RHD demonstrates the importance of on-going work in developing and evaluating 
research translation initiatives. 
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TEXT 
INTRODUCTION 
Acute rheumatic fever (ARF) is an autoimmune response to infection with group A 
streptococcus (GAS).1 It is associated with inflammation of the heart, skin, brain and joints. 
While episodes of ARF are usually self-limiting the immune response may result in heart 
valve damage, particularly of the mitral or aortic valve. This chronic condition is called 
rheumatic heart disease (RHD).1 RHD is more likely to develop after repeated episodes of 
ARF. 
Owing to the difficulties in identifying and implementing effective primordial and 
primary prevention strategies, a core component of ARF/RHD management is secondary 
prevention. Secondary prevention aims to protect individuals who have previously had ARF, 
or already have RHD, against GAS infection. This in turn protects these individuals against 
recurrent ARF and development or progression of valve damage associated with RHD. 
One aspect of secondary prevention is antibiotic prophylaxis in the form of three to 
four-weekly long-acting intramuscular benzathine penicillin injections (LAB).1-3 LAB has 
been demonstrated to be effective in preventing recurrent episodes of ARF and modelling 
suggests that secondary prophylaxis is the most cost-effective means of controlling RHD 
(US$142 per disability-adjusted life year gained and US$5520 per death averted).2, 4-6 While 
oral penicillin can be used in secondary prevention, it is less effective than LAB in preventing 
ARF.2, 7 Hence LAB remains the recommended treatment for secondary prophylaxis except 
in cases of demonstrated penicillin hypersensitivity.1 
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While the effectiveness of secondary antibiotic prophylaxis has been demonstrated8, 
delivery of LAB can be difficult. ARF/RHD patients not receiving adequate secondary 
prophylaxis are at risk of avoidable and progressive heart damage. Suboptimal delivery of 
secondary antibiotic prophylaxis has been highlighted in numerous countries including 
Australia9, Egypt10, Taiwan11, Brazil12 and South Africa.13 It has been suggested that low 
uptake may be due to the longevity and inconvenience of treatment (up to 20 years of LAB), 
the pain of injections, poor community engagement, inadequate patient education, cost and 
distance from health centres.14, 15 
Addressing the issue of low uptake of secondary antibiotic prophylaxis is an ongoing 
public health priority.14 The aim of this review is to evaluate the evidence pertaining to 
improving uptake of ARF/RHD prophylaxis within a framework of the Chronic Care Model 
(CCM) developed by Ed Wagner and colleagues.16 Given the longevity of secondary 
prophylaxis required for ARF/RHD patients, suboptimal uptake of treatment and the reality 
that delivery of health care in this context is far broader than individual interactions between 
patients and clinicians, it is timely to examine ARF/RHD secondary prophylaxis within a 
framework developed to improve chronic disease care. 
CHRONIC CARE MODEL FOR ARF/RHD 
There are a broad range of models of care that have been developed and utilized in 
chronic disease management.17-19 Many of these focus on specific chronic diseases20, 21, 
particular elements of treatment or the health care system22, defined providers23 or the client 
themselves.21, 24 Others are based on Wagner’s CCM and encompass a broader whole-of-
system approach that incorporates patient, provider and system-level interventions. The CCM 
has been utilized in this review as it provides a generic framework that is recognized and 
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utilized internationally and for a broad range of communicable and non-communicable 
chronic diseases.25-28  
The CCM highlights that effective chronic disease care results from positive 
relationships between empowered patients and proactive care teams. Wagner argues that 
delivering effective chronic disease care is best achieved through redesigning delivery 
systems within the context of three core domains: community resources, health care 
organization, and clinical practice (see Figure 1). 
While the CCM has been associated with improvements in chronic disease care16, 27, 28 
it has not been utilized specifically in relation to ARF/RHD. Furthermore, the model has 
limitations including the fact that there are few data relating to its cost-effectiveness and the 
potential difficulties in applying such a model of system redesign to regional and remote 
settings where many individuals with ARF/RHD live. Nonetheless, given the broad nature of 
the CCM framework it was considered the most suitable framework to use when examining 
potential strategies to improve the delivery of secondary antibiotic prophylaxis for 
ARF/RHD. 
SEARCH STRATEGY 
A PubMed search of English language articles was undertaken to identify literature 
relating to activities undertaken to improve uptake of secondary antibiotic prophylaxis for 
ARF/RHD. Published conference abstracts were included. The reference lists of retrieved 
articles were also searched. The search strategy included a combination of the following 
search terms: “secondary prophylaxis OR antibiotic prophylaxis OR benzathine penicillin OR 
preventive therapy”, “rheumatic fever OR rheumatic heart disease” and “adherence OR 
compliance”. A grey literature search was also undertaken examining the first ten pages of 
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Google and Google Scholar for the following search terms "secondary", "antibiotic", 
"prophylaxis", "penicillin", "rheumatic", "adherence" and "compliance". The criteria for the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were 
applied. 
In total 104 articles were reviewed. Articles which did not report adherence data for 
secondary prophylaxis or which did not describe interventions to improve uptake were 
excluded. Sixteen articles satisfied all selection criteria and were included. Given this low 
number, other potential strategies for improving uptake of secondary prophylaxis were 
discussed based on evidence from studies in other areas of health care. 
REVIEW OF INTERVENTIONS TO IMPROVE UPTAKE OF SECONDARY 
ANTIBIOTIC PROPHYLAXIS WITHIN A CCM FRAMEWORK 
1. Community Resources 
The CCM recognizes that the health care system is embedded within the wider 
community. It suggests that better patient outcomes may be expected if “community 
resources” are mobilized to meet the needs of patients.16 
Mobilizing community resources to improve delivery of ARF/RHD secondary 
prophylaxis may involve a broad range of initiatives. For example, health access may be 
improved through community-control, clinical outreach or developing linkages between 
health services and community-based agencies such as schools, sports bodies, stores, 
churches and welfare agencies. It may also be possible to promote secondary prophylaxis 
through community events and cultural activities. A thorough understanding of local 
community dynamics is likely to be integral to identifying potential community partners for 
such activities. 
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Within an indigenous context, research focused on Canada’s First Nations peoples has 
shown that community control of health services, self-governance, control of traditional lands 
and community-controlled schooling can improve health outcomes.29, 30 Nonetheless, this 
research was specifically related to youth suicide and may not be generalizable to chronic 
disease care in general and ARF/RHD specifically. 
Local events such as concerts and cultural gatherings may provide a useful forum for 
engaging young populations at particular risk of ARF. There is evidence that health 
promotion activities at such events can influence health-related behaviour including reducing 
tobacco consumption.31 However, no studies have been published regarding the possible role 
of community events in encouraging the uptake of ARF/RHD prophylaxis. 
The development of linkages between health care and education systems can be 
particularly effective in improving uptake of secondary prophylaxis by children and 
adolescents. One secondary prophylaxis program in Auckland, New Zealand, focused on 
community nurses delivering LAB injections at schools.32 Within a year of implementing this 
program significant improvements in uptake were reported. The proportion of clients 
receiving all scheduled injections ranging across nine sites ranged from 80% to 100%.  
There is some evidence that a ‘whole of community’ response to ARF/RHD 
prevention can be effective.33-35 Such an approach was implemented in the Cuban province of 
Pinar del Rio between 1986 and 1996.35 Five years after the program commenced the 
occurrence of ARF and RHD had declined by up to 90% and a progressive increase in uptake 
of secondary prophylaxis was reported. Community involvement and the utilization of public 
media were key components of this program. Similar success with ‘whole of community’ 
interventions has been reported in Costa Rica33 and the Caribbean34. Unfortunately it is 
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difficult to identify the exact elements which contribute to the success of such broad-scale 
programs. 
2. Health Care Organization 
The CCM highlights that to improve chronic disease care it is necessary to improve 
the quality and safety of the culture, systems and practices of health care organizations.16 To 
effect such change requires clinician leadership and advocacy from service providers, 
patients, community leaders and clinical and consumer organizations. 
One mechanism that is often used to refine health systems is continual quality 
improvement (CQI). CQI refers to a structured organizational process to plan and implement 
a continuous suite of interventions to improve the quality of health care provided by an 
organization.36 It involves examining and reworking existing health care processes in light of 
best-practice, evidence-based knowledge and scientific methodologies.36 While systematic 
reviews have demonstrated that CQI can be effective in improving health care, the evidence 
is limited and improvements are generally small to moderate.37, 38 Moreover, positive results 
tend to be seen when baseline adherence to recommended practice is low and intensity of 
audit and feedback is high.39 CQI programs may be difficult to implement if they are 
complex, time-consuming and resource-intensive. These problems may be exacerbated in low 
resource, indigenous and remote settings40 where ARF/RHD are most prevalent.  
There are currently only limited published data reporting on the efficacy of CQI 
initiatives in ARF/RHD care. One study from the Northern Territory in Australia suggested 
that CQI activities did improve some aspects of ARF/RHD care but had no impact on the 
proportion of patients receiving >80% of their scheduled LAB injections.41 Thus, it remains 
unclear whether formal CQI initiatives are superior to other organizational strategies to 
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improve service delivery such as those that encourage reflective and responsive health care at 
an individual provider level. 
Providing incentives to health care providers may be another potential mechanism to 
improve patient care. In the context of ARF/RHD, secondary prophylaxis providers could be 
rewarded for each dose delivered or when uptake targets are met. While there is no published 
literature in relation to such ‘pay-for-performance’ (P4P) strategies for secondary prophylaxis 
there is evidence relating to other elements of health care. Systematic reviews by de Bruin et 
al.42 and Scott et al.43 revealed that P4P strategies can result in small improvements in the 
quality of care provided to patients but that most P4P studies included significant 
methodological limitations and no assessment of cost effectiveness. In contrast, a systematic 
review by Witter et al. of interventions in low to middle income countries found little to 
support the use of P4P in such settings.44 Furthermore, it has been argued that the complexity 
and design of P4P initiatives can make it difficult to generalize apparently successful 
initiatives to other settings.45 Despite these limitations, the success of some P4P schemes 
suggests that well designed incentive systems with clear evaluation strategies are worthy of 
further investigation as a mechanism to enhance ARF/RHD secondary prevention. 
3. Clinical Practice 
3(i) Self-management support 
The CCM recognizes that a central component to improving chronic disease care is to 
provide patients with the knowledge, skills, motivation and support to manage their own 
health.16 
An uncontrolled evaluation of a secondary prophylaxis program in Barbados 
demonstrated that supporting ARF/RHD patients to self-manage through the use of patient-
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carried cards to record injection dates may be effective.46, 47 This program was associated 
with an uptake of 97% of possible doses of therapy by patients. However, the specific impact 
of the patient cards could not be separated from other confounding factors including the fact 
that their introduction coincided with the establishment of an ARF/RHD clinic at the local 
hospital.  While a system of hand-held records may prove particularly useful for patients who 
are mobile and access health care at various sites there is little published evidence to support 
this. 
Another mechanism that may support self-management is the use of mobile 
telephone-based short message service (SMS) reminders. One review of SMS reminders 
found that they substantially increased the likelihood of patients attending clinic 
appointments.48 The increasing use of mobile telephones in  low resource and remote settings 
suggests that the use of SMS-based reminders may be a viable option to enhance ARF/RHD 
care across a broad range of settings.49, 50 Nonetheless, at present there is no published 
evidence to support this. 
When considering the concept of self-management in health care it is important to 
reflect on the extent to which individuals and communities may wish to take on such a role. 
An Australian study investigating ARF/RHD prophylaxis in a remote Aboriginal community 
found that a patient’s sense of taking responsibility for their own health was not clearly 
related to uptake.51 Rather, patients felt that the role of the health service was not only to 
provide medical care but also to perform a pastoral role in terms of home visits, engaging 
families, encouraging patients and caring for them emotionally. Another Australian study 
reported that the uptake of secondary prophylaxis was closely linked with positive patient–
staff interactions.52 These studies imply that in a remote Aboriginal context self-management 
for ARF/RHD may play a secondary role to the quality of relationships between health staff 
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and patients/families. Nonetheless, these findings may be specific to their contexts and not 
generalizable to other cultural situations. 
A key component of chronic disease self-management is patient, family and 
community education. ARF/RHD education has been associated with an improvement in the 
uptake of secondary prophylaxis in Costa Rica33 and the Caribbean.34 Furthermore, an 
Egyptian study showed that inadequate education of parents regarding ARF/RHD and 
secondary prophylaxis was the main factor jeopardising quality of care for their children.10 
Nonetheless, the Costa Rican and Caribbean studies were uncontrolled multi-dimensional 
interventions and so the isolated effects of education initiatives remain difficult to determine. 
It has been suggested that patient/carer incentives may be a useful tool to improve 
uptake of ARF/RHD secondary prophylaxis.14 Two recent Cochrane reviews of the 
effectiveness of incentives in limiting tobacco consumption53, 54 and a systematic review 
investigating the use of financial incentives for the treatment for obesity55  found that such 
schemes were not generally successful. Nonetheless, a review of eleven randomized 
controlled trials investigating the effect of financial incentives on compliance with 
medication, medical advice, or medical appointments did find a positive association.56 Given 
the lack of conclusive evidence supporting the effectiveness of patient incentives, and that 
there is no evidence relating to their use in the context of ARF/RHD prophylaxis, further 
research is required before recommendations can be made. 
3(ii) Delivery system design 
The CCM highlights that improvement in chronic disease outcomes requires the 
delivery of clinical care that is effective and efficient.16  
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It is often suggested that a key element in the successful delivery of secondary 
prophylaxis is having systems of patient registration and recall that are up-to-date, accessible 
and clear.34 Such systems are thought to be particularly useful in following up patients who 
miss LAB injections.1, 57 Nonetheless, the evidence supporting their effectiveness in 
enhancing secondary antibiotic prophylaxis is limited to uncontrolled audits.8, 35, 58 Under 
such conditions it is not possible to determine whether changes in prophylaxis uptake are due 
to the register/recall systems or other undefined factors. 
Successful delivery of secondary prophylaxis requires clarity regarding roles and 
responsibilities of clinical and non-clinical health staff. High uptake rates were reported for a 
New Zealand secondary prophylaxis program that involved community-based nurses working 
with ethnically appropriate health workers who provided education, support and transport.59 
Other studies have confirmed that uptake of secondary prophylaxis improves where clear 
responsibility is placed upon a particular staff member to actively follow-up clients who miss 
injections.52 
One study in central Australia investigated the novel concept of delivering secondary 
prophylaxis at times of the full moon.60 While uptake increased significantly it did not occur 
at the time of the full moon. Such findings reinforce the need to critically evaluate claims that 
any specific initiative has enhanced ARF/RHD secondary prophylaxis uptake when often 
confounders and other uncontrolled factors may not have been adequately addressed or 
controlled for in the study. 
3(iii) Decision support 
The CCM recognizes that clinical care provided to patients with chronic diseases must 
be based on current evidence while at the same time taking account of patient preferences.16 
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In respect of ARF/RHD care evidence-based best-practice guidelines are available for 
a number of settings including South Africa, Asia, North America, New Zealand, and 
Australia, and globally via the World Health Organisation.1, 8, 61-64 The CCM acknowledges 
the importance of incorporating such guidelines into existing care and register/recall systems. 
Nonetheless, these guidelines cite many of the studies already discussed in this review to 
support specific recommendations regarding secondary antibiotic prophylaxis. As outlined 
above, much of the evidence in these studies is limited. 
To improve decision-support regarding ARF/RHD secondary prophylaxis a number 
of specific issues need to be addressed. First, there must be clarity and consistency in relation 
to timing of delivery and period of coverage required. Unfortunately, even in high income 
countries such as Australia, adherence to national guidelines is variable.9 Second, support 
systems are required for local health providers to deal with more complicated management 
issues not adequately addressed by local ARF/RHD guidelines. Such systems may include 
accessing specialist or more experienced primary health care providers through telemedicine 
or outreach clinics. While there is no published evidence relating specifically to the use of 
telemedicine in secondary prophylaxis, one report noted that the use telemedicine in the 
Pacific Islands enabled more efficient and effective evaluation and follow up of RHD patients 
requiring surgical intervention.65 Third, as the severity of RHD dictates the frequency of 
health care review and the longevity of prophylaxis required1, routine review of patients and 
their medical records is needed to ensure that decision support systems are correctly applied. 
Such review can ensure that secondary prophylaxis is ceased when appropriate which would 
prevent patient inconvenience and unnecessary consumption of finite health resources.  
3(iv) Clinical information systems 
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Effective clinical information systems provide easy access to up-to-date patient and 
population data thereby allowing health practitioners to make well-informed decisions about 
patient care. A preferred system for facilitating the uptake of ARF/RHD prophylaxis is one 
that integrates patient information, decision support and recall and follow-up.1 The structure 
of any such system will be dependent upon available resources. In higher income settings this 
may include electronic patient medical records which interface with centralized ARF/RHD 
register/recall systems and electronic decision support. In other settings these may be paper-
based records, registers and protocols or hand held records. The effectiveness of such 
register/recall systems in improving uptake of secondary antibiotic prophylaxis has been 
discussed above. 
CONCLUSION 
The CCM provides a framework within which to plan, implement and evaluate 
initiatives to improve chronic disease services. Evidence suggests that the uptake of 
secondary antibiotic prophylaxis for ARF/RHD is often inadequate and hence we used the 
CCM framework to review interventions to improve service delivery. 
There is limited published evidence pertinent to improving the delivery of ARF/RHD 
secondary prophylaxis. That which is available suggests that register/recall systems, 
dedicated teams to deliver prophylaxis, ARF/RHD education, linkages with the community 
(particularly schools) and staff-patient relationships may be important. However, it is difficult 
to generalize findings from individual studies to other settings, and high quality studies are 
lacking.  
The problem of uptake of ARF/RHD secondary prophylaxis remains vexed. The 
solution to preventing ARF/RHD is likely to lie in understanding and addressing the role of 
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poverty, developing an effective GAS vaccine and researching new systems of delivery of 
secondary prophylaxis that do not require monthly injections over decades. In the interim the 
focus should be on developing and evaluating innovative programs to improve delivery of 
LAB. A current Australian multicentre community-based clinical trial evaluating a 
multidimensional primary health care based intervention to enhance secondary prophylaxis 
delivery may inform this process.66 
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FIGURE LEGENDS 
 
Figure 1 Diagrammatic representation of the Chronic Care Model.16, 19 
 
